Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets

被引:64
作者
Saxena, Aaruni [2 ]
Balaramnavar, Vishal M. [1 ]
Hohlfeld, Thomas [2 ]
Saxena, Anil K. [1 ]
机构
[1] CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226001, Uttar Pradesh, India
[2] Univ Dusseldorf, Inst Pharmakol & Klin Pharmakol, D-40225 Dusseldorf, Germany
关键词
Aspirin; Drug/drug interaction; Molecular modeling; Aggregation; Thromboxane; PHARMACODYNAMIC INTERACTION; IBUPROFEN; PHARMACOKINETICS; INHIBITION; DICLOFENAC; NAPROXEN; DISEASE; ANALOGS; RISK;
D O I
10.1016/j.ejphar.2013.09.032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonsteroiclal anti-inflammatory drugs (NSAIDs) may interfere with the anti platelet activity of aspirin at the level of the platelet cyclooxygenase-1 (COX-1) enzyme. In order to examine the interference of common NSAIDs with the anti-platelet activity of aspirin the human platelet rich plasma from voluntary donors was used for arachidonic acid-induced aggregation and determination of thromboxane synthesis. Further, docking studies were used to explain the molecular basis of the NSAID/aspirin interaction. The experimental results showed that celecoxib, dipyrone (active metabolite), ibuprofen, Ilufenamic acid, naproxen, nimesulide, oxaprozin, and piroxicam significantly interfere with the anti-platelet activity of aspirin, while diclolenac, ketorolac and acetaminophen do not. Docking studies suggested that NSAIDs forming hydrogen bonds with Ser530, Arg120, Tyr385 and other amino acids of the COX-1 hydrophobic channel interfere with antiplatelet activity of aspirin while non interfering NSAIDs do not form relevant hydrogen bond interactions within the aspirin binding site. In conclusion, docking analysis of NSAID interactions at the COX-1 active site appears useful to predict their interference with the anti-platelet activity of aspirin. The results, demonstrate that some NSAIDs do not interfere with the antiplatelet action of aspirin while many others do and provide a basis for understanding the observed differences among individual non-aspirin NSAIDs. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:215 / 224
页数:10
相关论文
共 39 条
[1]   Design, synthesis and evaluation of aspirin analogues having an additional carboxylate substituent for antithrombotic activity [J].
Alagha, Ahmed ;
Moman, Edelmiro ;
Adamo, Mauro F. A. ;
Nolan, Kevin B. ;
Chubb, Anthony J. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) :4213-4216
[2]   Low-Dose Naproxen Interferes With the Antiplatelet Effects of Aspirin in Healthy Subjects [J].
Anzellotti, Paola ;
Capone, Marta L. ;
Jeyam, Anita ;
Tacconelli, Stefania ;
Bruno, Annalisa ;
Tontodonati, Paola ;
Di Francesco, Luigia ;
Grossi, Linda ;
Renda, Giulia ;
Merciaro, Gabriele ;
Di Gregorio, Patrizia ;
Price, Thomas S. ;
Garcia Rodriguez, Luis A. ;
Patrignani, Paola .
ARTHRITIS AND RHEUMATISM, 2011, 63 (03) :850-859
[3]   Clinical pharmacokinetics of nimesulide [J].
Bernareggi, A .
CLINICAL PHARMACOKINETICS, 1998, 35 (04) :247-274
[4]   A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease [J].
Biondi-Zoccai, Giuseppe G. L. ;
Lotrionte, Marzia ;
Agostoni, Pierfrancesco ;
Abbate, Antonio ;
Fusaro, Massimiliano ;
Burzotta, Francesco ;
Testa, Luca ;
Sheiban, Imad ;
Sangiorgi, Giuseppe .
EUROPEAN HEART JOURNAL, 2006, 27 (22) :2667-2674
[5]   Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition [J].
Brenneis, Christian ;
Maier, Thorsten J. ;
Schmidt, Ronald ;
Hofacker, Annette ;
Zulauf, Lars ;
Jakobsson, Per-Johan ;
Scholich, Klaus ;
Geisslinger, Gerd .
FASEB JOURNAL, 2006, 20 (09) :1352-1360
[6]   Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects [J].
Capone, ML ;
Sciulli, MG ;
Tacconelli, S ;
Grana, M ;
Ricciotti, E ;
Renda, G ;
Di Gregorio, P ;
Merciaro, G ;
Patrignani, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (08) :1295-1301
[7]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[8]   Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects [J].
Critchley, JAJH ;
Critchley, LAH ;
Anderson, PJ ;
Tomlinson, B .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2005, 30 (02) :179-184
[9]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[10]  
Gehlhaar D.K., 1998, Proceedings of the Seventh International Conference on Evolutionary Programming, P449